New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas

路德维希港（Ludwigshafen）新的最先进的研发设施，旨在扩大核心治疗领域新药的发现和开发

Investment reinforces the importance of the Rhineland-Palatinate site within AbbVie’s global network

投资增强了艾伯维全球网络中莱茵兰Palatinate网站的重要性

Construction of the new R&D building expected to complete in 2027

新研发大楼预计于2027年完工

LUDWIGSHAFEN, Germany, April 29, 2024 – AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150 million in its second largest R&D location worldwide. A state-of-the-art research and laboratory building is being built on the main campus and will be home to more than 300 researchers and scientists.

2024年4月29日，德国路德维希港——AbbVie在一座新的中央研究大楼“LUnA”（路德维希港新阿尔贝斯韦特）破土动工，并在其全球第二大研发基地投资约1.5亿欧元。主校区正在建造一座最先进的研究和实验室大楼，将容纳300多名研究人员和科学家。

The facility will be built with modern and sustainable infrastructure features, creating flexible working conditions that enable greater scientific exchange between different areas of research and implement automation and digital research capabilities..

该设施将具有现代化和可持续的基础设施功能，创造灵活的工作条件，使不同研究领域之间能够进行更大的科学交流，并实现自动化和数字研究能力。。

Clemens Hoch, Minister for Science and Health of Rhineland-Palatinate; Tom Hudson, MD, Senior Vice President, Global Research, Chief Scientific Officer, AbbVie; Azita Saleki-Gerhardt, Ph.D., Executive Vice President, Chief Operations Officer, AbbVie and Chairman of the Supervisory Board of AbbVie Germany; Martin Gastens, Ph.D., Vice President Biologics Drug Product Development & Managing Director Research and Development at AbbVie Germany; Malu Dreyer, Minister President of Rhineland-Palatinate; Mario Brandenburg, Parliamentary State Secretary at the Federal Ministry of Education and Research; Petra Dick-Walther, State Secretary for Economic Affairs in Rhineland-Palatinate and Jutta Steinruck, Mayor of the City of Ludwigshafen.

莱茵兰-帕拉蒂纳州科学与卫生部长克莱门斯·霍赫；医学博士汤姆·哈德森（TomHudson），全球研究高级副总裁，艾伯维首席科学官；Azita Saleki Gerhardt博士，AbbVie执行副总裁、首席运营官兼AbbVie德国监事会主席；Martin Gastens博士，德国AbbVie生物制剂药品开发副总裁兼研发总经理；莱茵兰-帕拉蒂纳州部长兼总统马鲁·德雷耶；马里奥·勃兰登堡，联邦教育和研究部议会国务秘书；莱茵兰-帕拉提纳州经济事务国务秘书佩特拉·迪克·沃尔特（PetraDickWalther）和路德维希港市市长朱塔·斯坦鲁克（JuttaSteinruck）。

With this investment, AbbVie reinforces that the Rhineland-Palatinate site, with its more than 2,000 employees, will continue to be a critical component of AbbVie’s global network. All employees make a significant contribution to successfully advancing AbbVie's pipeline with the goal of developing new therapies for serious diseases across oncology, neuroscience and immunology that can potentially improve the lives of millions of patients..

通过这项投资，艾伯维进一步强调，拥有2000多名员工的莱茵兰-帕拉蒂纳网站将继续成为艾伯维全球网络的重要组成部分。所有员工都为成功推进艾伯维的管道做出了重大贡献，目标是为肿瘤学、神经科学和免疫学领域的严重疾病开发新疗法，从而有可能改善数百万患者的生活。。

“For AbbVie Germany, the new construction of our 'LUnA' research building is much more than a €150 million investment in cutting-edge infrastructure. It is a promise for the future of AbbVie science and innovation. We are creating attractive working conditions for our top scientists and attracting new talent so that we can conduct cutting-edge research at our site in the long term,” explains Martin Gastens, vice president, biologics drug product development and managing director R&D, AbbVie Germany..

AbbVie Germany生物制剂药品开发副总裁兼研发总监Martin Gastens解释道：“对于AbbVie Germany来说，我们‘LUnA’研究大楼的新建工程比尖端基础设施投资1.5亿欧元要多得多。这是对AbbVie科学和创新未来的承诺。我们正在为顶尖科学家创造有吸引力的工作条件，并吸引新人才，以便我们能够长期在我们的现场进行尖端研究。”。。

'The German state of Rhineland-Palatinate is on track to become one of the leading hubs for biotechnology and life sciences. We support research, promote its translation, and continue expanding the footprint. As the Government of the Federal State of Rhineland-Palatinate, we are proud of this additional investment made by AbbVie, and the trust which yet another large pharmaceutical company has placed in our state.

“德国莱茵兰-帕拉蒂纳州有望成为生物技术和生命科学的领先中心之一。我们支持研究，促进其翻译，并继续扩大足迹。作为莱茵兰-帕拉蒂纳联邦州政府，我们为AbbVie的额外投资以及另一家大型制药公司对我们州的信任感到骄傲。

We are working tirelessly on creating the best possible framework conditions for business and research and are collaborating closely in a network with all those involved through the biotechnology advisory board and the biotechnology academy. We are actively encouraging companies to put down roots and to invest in our Federal State, and once again I'd like to express my heartfelt thanks to AbbVie for the excellent collaboration, the sharing of experiences and the great investment,' said Rhineland Palatinate’s Minister President Malu Dreyer..

我们正在不懈努力，为商业和研究创造尽可能最佳的框架条件，并通过生物技术咨询委员会和生物技术学院与所有相关人员密切合作。莱茵兰-帕拉蒂纳特（Rhineland-Palatinate）部长兼总统马鲁·德雷耶（MaluDreyer）说：“我们正在积极鼓励公司扎根并在我们的联邦州投资，我要再次衷心感谢艾伯维（AbbVie）的出色合作、经验分享和巨大投资。”。。

Gastens adds, “We are very pleased that the Federal Government has taken action with the pharmaceutical strategy and has begun to make Germany a pharmaceutical location fit for the future. After all, the political framework is critical for future investment decisions.”

加斯滕斯补充道：“我们非常高兴联邦政府已采取行动实施制药战略，并已开始使德国成为适合未来的制药基地。毕竟，政治框架对未来的投资决策至关重要。”

“Our Ludwigshafen site serves as a center of excellence for both research and development and pharmaceutical manufacturing and will play a critical role in AbbVie’s future growth,” said Azita Saleki-Gerhardt, Ph.D., executive vice president, chief operations officer. 'This new expansion represents the proud continuation of our decades-long partnership with Germany – where we have invested approximately €250 million euros since 2020.”.

执行副总裁兼首席运营官Azita Saleki Gerhardt博士说：“我们的路德维希港工厂是研发和制药制造的卓越中心，将在艾伯维未来的发展中发挥关键作用。”这一新的扩张代表着我们与德国数十年合作关系的骄傲延续，自2020年以来，我们在德国投资了约2.5亿欧元。”。

“LUnA will offer our researchers in Ludwigshafen the most modern working conditions and, thanks to its structure, will further strengthen scientific exchange between different areas of research,” explains Tom Hudson, MD, senior vice president, global research, chief scientific officer, AbbVie. “I am particularly looking forward to seeing how we will further develop the future of laboratory automation and digital research in Ludwigshafen in our pursuit of discovering and developing breakthrough medicines for patients.”.

“LUnA将为路德维希港的研究人员提供最现代化的工作条件，由于其结构，将进一步加强不同研究领域之间的科学交流，”AbbVie全球研究高级副总裁兼首席科学官Tom Hudson医学博士解释道。“我特别期待看到我们将如何进一步发展路德维希港实验室自动化和数字研究的未来，以寻求为患者发现和开发突破性药物。”。

The groundbreaking ceremony was attended by distinguished guests including Rhineland Palatinate Minister President Malu Dreyer; Mario Brandenburg, Parliamentary State Secretary to the Federal Minister of Education and Research in Germany; Jutta Steinruck, Lord Mayor of the City of Ludwigshafen, as well as global AbbVie representatives.

出席奠基仪式的贵宾包括莱茵兰-帕拉蒂纳部长马鲁·德雷耶总统；马里奥·勃兰登堡（MarioBrandenburg），德国联邦教育和研究部长的议会国务秘书；路德维希港市长朱塔·斯坦鲁克（JuttaSteinruck）以及阿巴维全球代表。

The research building is expected to be completed in 2027..

研究大楼预计于2027年完工。。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube..

有关AbbVie的更多信息，请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X（以前的Twitter）和YouTube上关注@AbbVie。。

Media Contacts:

媒体联系人：

Jane Woo

简·吴

+1 (224) 864 3846

+1 (224) 864 3846

jane.woo@abbvie.com

jane.woo@abbvie.com

Fabian Liboschik

Fabian Liboschik

+49 1721820848

+49 1721820848

fabian.liboschik@abbvie.com

fabian.liboschik@abbvie.com